Skip to content

Minimal ACCess Hernia InguinAlis Treatment of Hernia

Minimal ACCess Hernia InguinAlis Treatment of Hernia (MACCHIATOH Study): Prospective Cohort Study of Single-port Robotic Suprapubic Inguinal Hernia Repair (SPIN Procedure)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07756749
Acronym
MACCHIATOH
Enrollment
30
Registered
2026-08-11
Start date
2026-08-02
Completion date
2029-08-01
Last updated
2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal Hernia Repair

Keywords

Inguinal hernia repair, da Vinci SP Surgical System, Suprapubic inguinal hernia repair

Brief summary

Evaluation of the perioperative and patient reported outcomes of a new surgical technique: single-port robotic suprapubic inguinal hernia repair (SPIN procedure).

Detailed description

The MACCHIATOH study (Minimal ACCess Hernia InguinAlis Treatment of Hernia) is a prospective, single-centre, single-arm IDEAL Stage 2b cohort study conducted at AZ Maria Middelares (Ghent, Belgium). The study evaluates a novel single-port robotic suprapubic inguinal hernia repair technique (SPIN procedure) in a consecutive series of 30 patients undergoing primary inguinal hernia repair. The SPIN procedure was developed to overcome some limitations of previously described single-port robotic approaches by using a suprapubic access route, which may provide improved access to the myopectineal orifice and potentially reduce the risk of access-site incisional hernias. The study hypothesizes that the SPIN procedure is a safe and efficient technique without increased complication risk and may result in less postoperative pain, improved cosmetic outcomes, and equal or better patient satisfaction compared with current minimally invasive approaches. Patients will be followed for 12 months postoperatively.

Interventions

PROCEDUREsingle-port robotic suprapubic inguinal hernia repair

single-port robotic suprapubic inguinal hernia repair

Sponsors

Algemeen Ziekenhuis Maria Middelares
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults with a primary inguinal hernia, either unilateral or bilateral

Exclusion criteria

* Recurrent inguinal hernia after preperitoneal repair * Irreducible scrotal hernia * Post-prostatectomy * Laparotomy in the lower abdomen * Pregnancy * Contra-indication for general anaesthesia

Design outcomes

Primary

MeasureTime frameDescription
Operative timeDuring surgeryTotal operative time from skin incision to skin closure
Technical errors with the robotic systemDuring surgeryNumber and type of technical errors or device-related issues encountered during the procedure.
Complication RateFrom surgery until 1 month postoperativelyIntraoperative, in-hospital and postoperative complications classified according to the Clavien-Dindo classification

Secondary

MeasureTime frameDescription
EuraHS Quality of Life scorePreoperatively, 1 month and 1 year postoperativelyPatient-reported quality of life assessed using the European Registry for Abdominal Wall Hernias Quality of Life (EuraHS-QoL) Questionnaire, a validated instrument evaluating pain at the hernia site, restriction of activities, and cosmetic discomfort. The total EuraHS-QoL score ranges from 0 to 90, with lower scores indicating better quality of life and less symptom burden, and higher scores indicating worse quality of life and greater symptom burden.
Body Image Questionnaire ScorePreoperatively, 1 month , and 1 year postoperativelyPatient-reported body image assessed using the Body Image Questionnaire. The questionnaire evaluates patient satisfaction with physical appearance and cosmetic outcomes
hernia recurrence1 year postoperativelyPresence of recurrent hernia assessed clinically and confirmed by ultrasound when clinically indicated.

Countries

Belgium

Contacts

CONTACTFilip Muysoms, MD, PhD
filip.muysoms@gmail.com+32477325710
CONTACTJolien Lansens, Study coordinator
Jolien.Lansens@mijnziekenhuis.be+3292461854

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 5, 2026